Article Sidebar
Views PDF: 67
ASSESSMENT OF TREATMENT OUTCOMES AND ADVERSE EFFECTS OF CHEMOTHERAPY WITH 4AC-4T AMONG STAGE III BREAST CANCER AT PHU THO PROVINCIAL GENERAL HOSPITAL
Main Article Content
Abstract
Objectives: To evaluate treatment outcomes and adverse effects of chemotherapy with 4AC-4T regimen among patients with stage III breast cancer at Phu Tho Provincial General Hospital. Methods: An uncontrolled clinical intervention study on 58 patients with stage III breast cancer. The implementation period is from January 2015 to September 2020. Results: 96.6% of patients had clinical response to 4AC-4T chemotherapy regimen (65.6% partial response and 31% complete response). 24.1% of patients had response on histopathology (pCR: ypT0/is-ypN0) (1.7% partial response and 22.4% complete response). 100% of patients were treated with 8 cycles of chemotherapy. 52.4% had neutropenia of all degrees (grade 3-4 accounted for 5.1%), 45.1% had hemoglobin, 6.9% had thrombocytopenia. 37.9% of patients recorded peripheral neurotoxicity level 1, 2. Conclusion: Applying chemotherapy by 4AC-4T regimen among patients with stage III breast cancer had high treatment response rate. The adverse effects recorded were all mild (Grade 1, 2).
Article Details
References
2. Lv L, Zhao B, Kang J et al (2022). Trend of disease burden and risk factors of breast cancer in developing countries and territories, from 1990 to 2019: Results from the Global Burden of Disease Study 2019. Front Public Health, 10, 1078191.
3. Waks A.G and Winer E.P (2019). Breast Cancer Treatment: A Review. Jama, 321(3), 288-300.
4. Hong W.S, Jeon J.Y, Kang S.Y et al (2013). Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer. J Korean Surg Soc, 85(1), 7-14.
5. Nguyễn Thị Thủy (2016). Đánh giá kết quả hóa trị bổ trợ trước phác đồ 4AC-4T trên bệnh nhân ung thư vú giai đoạn III, Luận văn thạc sỹ y học, Trường Đại học Y Hà Nội.
6. Hà Thành Kiên (2018). Đánh giá kết quả hóa trị trước phẫu thuật phác đồ 4AC-4T liều dày trên bệnh nhân ung thư vú tại Bệnh viện K, Luận văn Bác sĩ nội trú, Trường Đại học y Hà Nội.
7. Lê Thanh Đức (2014). Nghiên cứu hiệu quả hóa trị bổ trợ trước phẫu thuật phác đồ AP trong ung thư vú giai đoạn III, Luận án Tiến sĩ Y học, Đại học Y Hà Nội.
8. Evans T.R, Yellowlees A, Foster E et al (2005). Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol, 23 (13), 2988-95.
9. Melichar B, Hornychová H, Kalábová H et al (2012). Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis. Med Oncol, 29(4), 2577-85.